Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANX007 in Metastatic Castration-Resistant Prostate Cancer
NCT05519449Phase 1Recruiting
- Sponsor
- Janux Therapeutics
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, open-label trial of JANX007 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Janux Therapeutics. Primary endpoints: Dose Limiting Toxicities at 3 years and Adverse Events and Serious Adverse Events at 3 years. Started Sep 2022; status: recruiting.
02
Drugs
JANX007
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05519449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519449.